SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-039993
Filing Date
2023-11-09
Accepted
2023-11-09 08:00:39
Documents
13
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39363
2 ex99-1.htm EX-99.1 181773
  Complete submission text file 0001493152-23-039993.txt   417766

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE prph-20231109.xsd EX-101.SCH 3027
4 XBRL LABEL FILE prph-20231109_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE prph-20231109_pre.xml EX-101.PRE 22367
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3319
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 231390132
SIC: 2834 Pharmaceutical Preparations